LPCN — Lipocine Cashflow Statement
0.000.00%
Last trade - 00:00- $17.52m
- -$4.11m
- $11.20m
- 33
- 33
- 33
- 24
Annual cashflow statement for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21 | -0.634 | -10.8 | -16.4 | 0.008 |
| Depreciation | |||||
| Non-Cash Items | 4.14 | 0.817 | -0.296 | -0.511 | -0.306 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.52 | -4.59 | -0.924 | 4.97 | -0.964 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -15.3 | -4.41 | -12 | -11.9 | -1.22 |
| Capital Expenditures | — | -0.008 | -0.134 | -0.013 | -0.09 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.89 | -43.8 | 14.4 | 13.1 | 2.54 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 3.89 | -43.8 | 14.3 | 13.1 | 2.45 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20.9 | 26.9 | -2.13 | 0.405 | 0.209 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.49 | -21.3 | 0.198 | 1.62 | 1.43 |